Mr. Mark Upsdell reports

RAPID DOSE THERAPEUTICS REINFORCES STRATEGIC STRENGTH AND GLOBAL GROWTH TRAJECTORY

Rapid Dose Therapeutics Corp. has provided shareholders with a strategic update highlighting its continued execution, operational resilience and expanding global footprint.

In an environment marked by global market volatility and geopolitical uncertainty, Rapid Dose Therapeutics is uniquely positioned with a business model that remains largely insulated from external disruptions. The company's operations are not dependent on oil-linked inputs or global shipping constraints, and its cost structure is primarily composed of stable, fixed components. This positioning enables Rapid Dose Therapeutics to maintain operational continuity and focus squarely on long-term value creation.

Since the beginning of 2026, Rapid Dose Therapeutics has achieved several meaningful milestones that further derisk its growth strategy and strengthen its position across key international markets.

Key strategic developments

Global intellectual property expansion -- India patent grant

Rapid Dose Therapeutics, alongside its partner Aavishkar Oral Strips Pvt. Ltd., has secured a significant patent (IN 582202) from the Indian Patent Office for its nicotine bilayer oral film. This achievement enhances the company's intellectual property portfolio within one of the world's fastest-growing nicotine alternative markets and reinforces its broader global IP strategy under the Patent Cooperation Treaty framework with potential protection across 158 jurisdictions worldwide.

Advancing global tobacco collaboration

The company continues to build momentum in its fourth year of collaboration with a major global tobacco partner. Continuing pharmacokinetic (PK) trials are designed to demonstrate that Rapid Dose Therapeutics' QuickStrip nicotine formulation can replicate the rapid absorption profile of traditional cigarettes -- delivering effective craving management without the harmful effects of combustion.

Expansion into Brazil's health care market

Following regulatory approval from ANVISA, Rapid Dose Therapeutics has successfully launched its QuickStrip medical cannabis product in Brazil unlocking access to one of the largest pharmaceutical and health care markets in Latin America. This milestone highlights the company's ability to navigate regulatory frameworks and expand into high-growth international markets.

Enhanced U.S. market presence

Rapid Dose Therapeutics' recent listing on the OTCQB Venture Market under the symbol RDTCF marks a significant step in expanding U.S. investor access, improving liquidity and increasing overall market visibility.

Clinical validation and research progress

The company continues to advance its clinical research initiatives, including a CBD bioavailability study conducted in collaboration with the University of Regina and the University of Saskatchewan. Supported by research funding from the National Football League (NFL), the study has already generated data from over 60 per cent of participants, further supporting the efficacy and potential of the QuickStrip platform.

2026 strategic priorities

Rapid Dose Therapeutics remains focused on executing key growth initiatives, including:

• Expanding into regulated international markets through strategic partnerships;
• Strengthening distribution channels for natural health products;
• Advancing clinical research and validation across multiple verticals;
• Scaling and securing regulatory approval for Canadian manufacturing capabilities, including pharmaceutical-grade production.

These initiatives collectively position Rapid Dose Therapeutics to capitalize on opportunities across pharmaceutical, nutraceutical, nicotine and wellness sectors.

Leadership commentary

"Our momentum in 2026 reflects the strength of our strategy and the scalability of the QuickStrip platform," said Mark Upsdell, chief executive officer of Rapid Dose Therapeutics. "With a resilient operating model and continued progress across IP, clinical development and global markets, RDT is well insulated from current macroeconomic pressures and exceptionally well positioned to deliver sustainable, long-term value for our shareholders."

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.